Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify biomarker to predict response of colon cancer patients to chemotherapy regimen

07.06.2004


Researchers at Fox Chase Cancer Center have identified a biomarker that can predict how well individual colon cancer patients will respond to a common chemotherapy regimen. This finding is a significant step forward in the goal of personalizing cancer treatment. Medical oncologist Neal J. Meropol, M.D., director of the gastrointestinal cancer program at Fox Chase, presented the study today in New Orleans at the 40th Annual Meeting of the American Society of Clinical Oncology.



The study involves an enzyme that is important in activating capecitabine. Capecitabine is a commonly used oral chemotherapy drug that is converted into its active form by the enzyme thymidine phosphorylase (TP). TP is found in some, but not all, cancers. Capecitabine (marketed by Roche under the name Xeloda) in combination with irinotecan ( marketed by Pfizer under the name Camptosar) is a chemotherapy regimen being developed to treat advanced colon cancer patients.

Meropol’s study was designed to see if a correlation exists between how well a patient with metastatic colorectal cancer responds to chemotherapy with capecitabine plus irinotecan, and whether or not the amount of TP in the tumor predicted success with therapy. The study included 67 patients, ranging in age from 40 to 81, who had received no prior chemotherapy for their metastatic disease.


Patients whose tumors had the enzyme TP, believed to be needed in the final step to convert capecitabine to its active form of 5-FU (fluorouracil), had a significantly higher response rate to the chemotherapy regimen. Specifically, the response rate for patients whose primary tumors tested positive for TP was 65 percent compared to 27 percent in patients whose primary tumors tested negative for TP. Among patients whose metastatic tumors expressed TP, the response rate was 61 percent compared to 14 percent in patients without TP in metastases.

"These data suggest that TP expression may be useful as a marker in predicting a positive response to chemotherapy with capecitabine plus irinotecan for colorectal cancer patients," Meropol said. "With that information, we can begin personalizing treatment. If we know the enzyme is present to activate the drug, we may be able to identify those patients who should receive capecitabine."



Capecitabine is also used for patients with breast cancer.

The American Cancer Society estimates that nearly 147,000 Americans will receive a diagnosis of colon or rectal cancer this year and about 56,730 people will die of colorectal cancer in 2004. Meropol’s colleagues in the study include P. J. Gold of the Swedish Cancer Institute, Seattle Wash.; R. B. Diasio of the University of Alabama, Birmingham; Y. Chen and T. Hill of Roche Labs, Nutley, N.J.; T. Godfrey of Loma Linda University, Loma Linda, Calif.; A. J. Kovatich of MDR Global Systems, Windber, Pa.; K. A. Lund of Rockwood Clinic, Spokane, Wash.; and E. Mitchell and R. Schwarting of Thomas Jefferson University, Philadelphia.

Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa. as the nation’s first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center’s web site at www.fccc.edu or call 1-888-FOX CHASE.

Karen C. Mallet | EurekAlert!
Further information:
http://www.fccc.edu/

More articles from Health and Medicine:

nachricht The end of pneumonia? New vaccine offers hope
23.10.2017 | University at Buffalo

nachricht Scientists track ovarian cancers to site of origin: Fallopian tubes
23.10.2017 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>